We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.
This gives us the potential to revolutionise how people think about brain health and disease management.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
A huge thank you to Dr Reisa Sperling for attending our guest speaker series. Dr Sperling provided some key insights into the importance of undertanding preclinical Alzheimer's disease. By sharing her experience and knowledge from a number of ongoing clincial studies, the discussions stressed that early diagnosis and detection of Amyloid and Tau in cognitively healthy subjects will lead patients and families to take early action regarding their Brain Health. Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer’s disease, even before clinical symptoms are evident. She is the co-Principal Investigator, with Dr. Keith Johnson, of the Harvard Aging Brain Study in Boston. Her research uses neuroimaging and cognitive tests to understand the aging brain and the earliest changes associated with Alzheimer’s disease.
Dr Steven Chance and Omar Ehsan will be attending CTAD 2022 in San Francisco. Important readouts from lates mAbs interventions and the global AD community is anxiously waiting for the details. We will present two posters. Come along and chat to us. We have plenty to share, say and play our part in defeating this terrible condition. Our two posters: LP60 – Prediction of longitudinal change in CDR Sum of Boxes using a cortical microstructural AD signature from baseline diffusion MRI LP61 – Cortical microstructural measures from diffusion MRI correlate with cognitive composite scores and predict their longitudinal changes
It was a pleasure to welcome Professor Takeshi Iwatsubo to our guest speaker series. Takeshi Iwatsubo is a professor of neuropathology at the School of Medicine, University of Tokyo. Originally trained as a neurologist and neuropathologist, he has contributed to the studies of human neurodegenerative disorders, especially Alzheimer's (AD) and Parkinson's disease, using multidisciplinary approaches. Professor Iwatsubo provides a comprehensive review of the J-ADNI project and the insights to date. He further expanded on his laboratory's role to build a Japanese Trial Ready Cohort for preclinical/prodomal AD (J-TRAC). Progress is being made already with this approach, starting enrollment with the AHEAD, Trailblazer ALZ3 and other preclinical AD trials.
Dr Steven Chance and Omar Ehsan will be attending Alzheimer's Association International Conference 2022 in San Diego. We will present two posters. Come along and chat to us. We look forward to connecting with the AD global community and listening to all the wonderful scientific research and updates on clinicaltrials. We have plenty to share, say and play our part in defeating this terrible condition. Our two posters: 03 August (P4-199) - 'Regional pattern of cortical microstructural alterations along the AD continuum and association with plasma neurofilament light' 02 August (P3-189) - 'Ante mortem imaging of cortical microstructure relates to post mortem locus coeruleus hypopigmentation in autopsy-confirmed Alzheimer's disease'